


PHARMACEUTICAL 2017

Protea Biosciences Group Inc. Rank 279 of 313





PHARMACEUTICAL 2017

Protea Biosciences Group Inc. Rank 279 of 313

The relative strengths and weaknesses of Protea Biosciences Group Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Protea Biosciences Group Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 851% points. The greatest weakness of Protea Biosciences Group Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 453% points.

The company's Economic Capital Ratio, given in the ranking table, is -822%, being 405% points below the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	729
Cost of Goods Sold	1,706
Intangible Assets	0
Liabilities, Current	15,550
Liabilities, Non-Current	0
Other Assets	19
Other Compr. Net Income	-0.093
Other Expenses	0
Other Liabilities	0
Other Net Income	-10,155
Property and Equipment	2,466
Research and Development	602
Revenues	2,447
Selling, General and Administrative Expense	5,632

Output Variable	Value in 1000 USD
Assets	3,214
Liabilities	15,550
Expenses	7,940
Stockholders Equity	-12,336
Net Income	-15,648
Comprehensive Net Income	-15,648
Economic Capital Ratio	-822%